Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis

We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 1997-05, Vol.75 (9), p.1247-1255
Hauptverfasser: Bjørge, L, Junnikkala, S, Kristoffersen, EK, Hakulinen, J, Matre, R, Meri, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1255
container_issue 9
container_start_page 1247
container_title British journal of cancer
container_volume 75
creator Bjørge, L
Junnikkala, S
Kristoffersen, EK
Hakulinen, J
Matre, R
Meri, S
description We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.
doi_str_mv 10.1038/bjc.1997.213
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2228228</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9155042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-cdca62b55e69c8a146d0dd40be1cab8ea07c0e02026124d7f7af000c7dae978f3</originalsourceid><addsrcrecordid>eNp1kM9LwzAYhoMoc05vXoUcPNqZZG3TXgQZ_oKBKHoOX5OvW0bbjKQb7L83Y2PoQQiE8D55v4-HkGvOxpxNivtqqce8LOVY8MkJGfJsIhJeCHlKhowxmbBSsHNyEcIyPktWyAEZlDzLWCqG5OMTgw09dBqpq6nbgLfQ0R499E6D17ZzLVCNTUPDaoHeWRNo76h27arBFrs-adFY6NHQZhu7LslZDU3Aq8M9It_PT1_T12T2_vI2fZwlOpW8T7TRkIsqyzAvdQE8zQ0zJmUVcg1VgcCkZsgEEzkXqZG1hDrur6UBLGVRT0bkYd-7WldxAx038dColbct-K1yYNXfpLMLNXcbJYQo4okFd_sC7V0IHuvjX87UzqyKZtXOrIpmI37ze94RPqiM-e0hh6ChqX10asMRE3mWlbFnRJI9FmLSzdGrpVv7Lpr6byzd8x30a4_HvgjtmB3yA74FnjE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Bjørge, L ; Junnikkala, S ; Kristoffersen, EK ; Hakulinen, J ; Matre, R ; Meri, S</creator><creatorcontrib>Bjørge, L ; Junnikkala, S ; Kristoffersen, EK ; Hakulinen, J ; Matre, R ; Meri, S</creatorcontrib><description>We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1997.213</identifier><identifier>PMID: 9155042</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antibodies, Monoclonal - pharmacology ; Antibody-Dependent Cell Cytotoxicity - immunology ; Antigens, CD - biosynthesis ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; CD55 Antigens - biosynthesis ; CD59 Antigens - biosynthesis ; Complement Activation ; Complement Inactivator Proteins - biosynthesis ; Complement System Proteins - physiology ; Cytotoxicity, Immunologic - drug effects ; Drug Resistance ; Epidemiology ; experimental-oncology ; Female ; Female genital diseases ; Flow Cytometry ; Fluorescent Antibody Technique, Indirect ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Membrane Cofactor Protein ; Membrane Glycoproteins - biosynthesis ; Molecular Medicine ; Oncology ; Ovarian Neoplasms - immunology ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Spheroids, Cellular - immunology ; Spheroids, Cellular - metabolism ; Spheroids, Cellular - pathology ; Teratocarcinoma - immunology ; Teratocarcinoma - metabolism ; Teratocarcinoma - pathology ; Tumor Cells, Cultured ; Tumors</subject><ispartof>British journal of cancer, 1997-05, Vol.75 (9), p.1247-1255</ispartof><rights>Cancer Research Campaign 1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-cdca62b55e69c8a146d0dd40be1cab8ea07c0e02026124d7f7af000c7dae978f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228228/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228228/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2725,27923,27924,41487,42556,51318,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2655921$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9155042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bjørge, L</creatorcontrib><creatorcontrib>Junnikkala, S</creatorcontrib><creatorcontrib>Kristoffersen, EK</creatorcontrib><creatorcontrib>Hakulinen, J</creatorcontrib><creatorcontrib>Matre, R</creatorcontrib><creatorcontrib>Meri, S</creatorcontrib><title>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibody-Dependent Cell Cytotoxicity - immunology</subject><subject>Antigens, CD - biosynthesis</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>CD55 Antigens - biosynthesis</subject><subject>CD59 Antigens - biosynthesis</subject><subject>Complement Activation</subject><subject>Complement Inactivator Proteins - biosynthesis</subject><subject>Complement System Proteins - physiology</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>experimental-oncology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Flow Cytometry</subject><subject>Fluorescent Antibody Technique, Indirect</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Membrane Cofactor Protein</subject><subject>Membrane Glycoproteins - biosynthesis</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Spheroids, Cellular - immunology</subject><subject>Spheroids, Cellular - metabolism</subject><subject>Spheroids, Cellular - pathology</subject><subject>Teratocarcinoma - immunology</subject><subject>Teratocarcinoma - metabolism</subject><subject>Teratocarcinoma - pathology</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9LwzAYhoMoc05vXoUcPNqZZG3TXgQZ_oKBKHoOX5OvW0bbjKQb7L83Y2PoQQiE8D55v4-HkGvOxpxNivtqqce8LOVY8MkJGfJsIhJeCHlKhowxmbBSsHNyEcIyPktWyAEZlDzLWCqG5OMTgw09dBqpq6nbgLfQ0R499E6D17ZzLVCNTUPDaoHeWRNo76h27arBFrs-adFY6NHQZhu7LslZDU3Aq8M9It_PT1_T12T2_vI2fZwlOpW8T7TRkIsqyzAvdQE8zQ0zJmUVcg1VgcCkZsgEEzkXqZG1hDrur6UBLGVRT0bkYd-7WldxAx038dColbct-K1yYNXfpLMLNXcbJYQo4okFd_sC7V0IHuvjX87UzqyKZtXOrIpmI37ze94RPqiM-e0hh6ChqX10asMRE3mWlbFnRJI9FmLSzdGrpVv7Lpr6byzd8x30a4_HvgjtmB3yA74FnjE</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>Bjørge, L</creator><creator>Junnikkala, S</creator><creator>Kristoffersen, EK</creator><creator>Hakulinen, J</creator><creator>Matre, R</creator><creator>Meri, S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19970501</creationdate><title>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</title><author>Bjørge, L ; Junnikkala, S ; Kristoffersen, EK ; Hakulinen, J ; Matre, R ; Meri, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-cdca62b55e69c8a146d0dd40be1cab8ea07c0e02026124d7f7af000c7dae978f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibody-Dependent Cell Cytotoxicity - immunology</topic><topic>Antigens, CD - biosynthesis</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>CD55 Antigens - biosynthesis</topic><topic>CD59 Antigens - biosynthesis</topic><topic>Complement Activation</topic><topic>Complement Inactivator Proteins - biosynthesis</topic><topic>Complement System Proteins - physiology</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>experimental-oncology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Flow Cytometry</topic><topic>Fluorescent Antibody Technique, Indirect</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Membrane Cofactor Protein</topic><topic>Membrane Glycoproteins - biosynthesis</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Spheroids, Cellular - immunology</topic><topic>Spheroids, Cellular - metabolism</topic><topic>Spheroids, Cellular - pathology</topic><topic>Teratocarcinoma - immunology</topic><topic>Teratocarcinoma - metabolism</topic><topic>Teratocarcinoma - pathology</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bjørge, L</creatorcontrib><creatorcontrib>Junnikkala, S</creatorcontrib><creatorcontrib>Kristoffersen, EK</creatorcontrib><creatorcontrib>Hakulinen, J</creatorcontrib><creatorcontrib>Matre, R</creatorcontrib><creatorcontrib>Meri, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bjørge, L</au><au>Junnikkala, S</au><au>Kristoffersen, EK</au><au>Hakulinen, J</au><au>Matre, R</au><au>Meri, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>75</volume><issue>9</issue><spage>1247</spage><epage>1255</epage><pages>1247-1255</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>9155042</pmid><doi>10.1038/bjc.1997.213</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 1997-05, Vol.75 (9), p.1247-1255
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2228228
source MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings
subjects Antibodies, Monoclonal - pharmacology
Antibody-Dependent Cell Cytotoxicity - immunology
Antigens, CD - biosynthesis
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
CD55 Antigens - biosynthesis
CD59 Antigens - biosynthesis
Complement Activation
Complement Inactivator Proteins - biosynthesis
Complement System Proteins - physiology
Cytotoxicity, Immunologic - drug effects
Drug Resistance
Epidemiology
experimental-oncology
Female
Female genital diseases
Flow Cytometry
Fluorescent Antibody Technique, Indirect
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Membrane Cofactor Protein
Membrane Glycoproteins - biosynthesis
Molecular Medicine
Oncology
Ovarian Neoplasms - immunology
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
Spheroids, Cellular - immunology
Spheroids, Cellular - metabolism
Spheroids, Cellular - pathology
Teratocarcinoma - immunology
Teratocarcinoma - metabolism
Teratocarcinoma - pathology
Tumor Cells, Cultured
Tumors
title Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A42%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resistance%20of%20ovarian%20teratocarcinoma%20cell%20spheroids%20to%20complement-mediated%20lysis&rft.jtitle=British%20journal%20of%20cancer&rft.au=Bj%C3%B8rge,%20L&rft.date=1997-05-01&rft.volume=75&rft.issue=9&rft.spage=1247&rft.epage=1255&rft.pages=1247-1255&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1997.213&rft_dat=%3Cpubmed_cross%3E9155042%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9155042&rfr_iscdi=true